Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | AHR | P35869 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.40 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946635 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL4388586 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL29965849 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL12717303 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL27997203 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL16230664 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL10442032 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL21742008 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL16231361 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1AHRCHRM2BLM | |
| SCHEMBL4270539 | 0.80 | L3MBTL1 (0.73) | SMN1; SMN2L3MBTL1AHRBLMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117368160-A | Method for verifying iron death in neurodegenerative diseases and application of method | 西南医科大学 | 2024-01-09 | — | — | CN | claimed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | claimed |
| EP-1153919-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-11-14 | — | — | EP | claimed |
| EP-0435127-A2 | 3-Substituted pyridines | BASF Aktiengesellschaft (DE) | 1991-07-03 | — | — | EP | claimed |
| US-6642387-B2 | Dehalogenation esterification; efficient; no toxic materials | KANEKA CORPORATION (JP) | 2003-11-04 | — | — | US | disclosed |
| US-6642387-B2 | Dehalogenation esterification; efficient; no toxic materials | KANEKA CORPORATION (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| US-6515134-B1 | A production method of an optically active hydroxyethyl pyridine derivative represented by the general formula which comprises using a microorganism-derived carbonyl reducing enzyme or a culture of a microorganism having an ability of | KANEKA CORPORATION (JP) | 2003-02-04 | — | — | US | disclosed |
| US-6515134-B1 | A production method of an optically active hydroxyethyl pyridine derivative represented by the general formula which comprises using a microorganism-derived carbonyl reducing enzyme or a culture of a microorganism having an ability of | KANEKA CORPORATION (JP) | 2003-02-04 | — | — | US | disclosed |
| EP-1153919-A4 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORP (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1153919-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-1153919-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000048997-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE β3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2000-08-24 | — | — | WO | disclosed |
| US-5194441-A | Fungicides | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | ADRB3, ADRB2, ADRB1 | SMN1; SMN2 4103/4885L3MBTL1 4709/4885AHR 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.